XJPX
3671
Market cap48mUSD
Oct 09, Last price
316.00JPY
1D
0.00%
1Q
-3.36%
Jan 2017
-75.91%
IPO
-92.83%
Name
Softmax Co Ltd
Chart & performance
P/E
13.25
P/S
1.10
EPS
23.85
Div yield, %
3.16%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
11.48%
Revenues
6.93b
+27.62%
Net income
573m
+19.43%
CFO
389m
-41.42%
Dividend
Dec 29, 202610 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Softmax Co., Ltd handles the complete spectrum of corporate system services, encompassing their development, commercialization, deployment, and ongoing support. A significant portion of their work is dedicated to creating advanced medical information systems. Their offerings within the healthcare sector are diverse, comprising web-based electronic medical record (EMR) systems, online patient ordering platforms, medical financial management software, radiology information systems, and specialized solutions for rehabilitation departments, health screening, nursing task management, and surgical units. Established in 1974, Softmax Co., Ltd's corporate headquarters are located in Tokyo, Japan.
Key people
Toshiro Nomura
Chairman of the Board, Representative Director · since 2022
Tsutomu Matsushima
Vice Chairman of the Board · since 2024
Koichi Hamahira
Managing Director · since 2014
Munetoshi Nagasawa
Director of Central Japan Business Unit in Main Business Unit, Director · since 2023
Kazushi Shimotamari
Senior Director of 1st System Development Unit, Director · since 2022
Tatsuhiko Nomura
Managing Director · since 2022
Katsuji Saito
Managing Director · since 2018
Chieko Shimamori
President, Representative Director · since 2025
Daisuke Ueda
Director of Business Planning in Main Administration Unit, Director · since 2022
Takashi Aiko
Independent Director · since 2022
Shinichi Fukumoto
Independent Director · since 2016
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||